Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07442812 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Oral vs Intravenous Dexamethasone in Total Knee Arthroplasty

Study acronym: TKA
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 9 months later Dec 2026 → Oct 2027
See other at-risk trials from Haseki Training and Research Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 2026 to Oct 2027v4
  2. Notable Recruitment openedv3 Show 4 more changesShow less
    • Enrollment increased: 99 → 270 participants
    • Primary completion pushed from Aug 2026 to Dec 2026
    • Study completion pushed from Aug 2026 to Oct 2027
    • Site details revised
  3. Notable Primary endpoints: 3 to 4
    • Secondary endpoints revised (5)
    v2
  4. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This prospective observational cohort study aims to evaluate the association between perioperative dexamethasone administration and early postoperative recovery following primary total knee arthroplasty. In routine clinical practice, dexamethasone may be administered orally, intravenously, or not administered, depending on the surgeon's established perioperative protocol. The primary objective is to assess early postoperative recovery in terms of pain intensity, functional mobility, and knee joint range of motion. Secondary objectives include evaluation of inflammatory response, postoperative metabolic changes, opioid requirement, and the severity of postoperative nausea and vomiting (PONV). Group allocation is non-randomized and determined solely by the standard perioperative management approach routinely applied by the surgeon selected by the patient. No additional interventions are introduced for research purposes. All outcomes are assessed prospectively during the early postoperative period.
Trial Details
NCT Number NCT07442812
Lead Sponsor Haseki Training and Research Hospital
Conditions
(from sponsor)
Knee Osteoarthritis, Gonarthrosis; Primary, Total Knee Arthroplasty
Related terms Osteoarthritis, Knee
Enrollment 270 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov